July/August 2013

Growth hormone deficiency in children and adults is a disease state that utilizes growth hormone therapy. Here is what specialty pharmacists can do for these patients and what they should know about these conditions.

In the development of a specialty pharmacy strategy, there are many key stakeholders, but none more important than the pharmacy, payer, and product. Each has its own mission and goals; however, at some point they must all come together.

With the growth of specialty pharmacies in retail, there are new tracking and reporting challenges to consider and conquer.

Interactive, real-time, 24/7 patient connections will change the way patient care is delivered and offer new ways of doing business for specialty pharmacy.

Why are limited distribution networks found only in the United States? Does pharma know best?

The cost of complex therapies is soaring, and the challenge is to deliver access to these medications in the most cost-effective and clinically appropriate site of service.

Treatment advances have made many cancers a chronic disease rather than a terminal disease. Here is how one dedicated team works to coordinate care and work with patients.

A significant number of new specialty medications are on track to be approved in 2013, and some will provide increased competition in certain therapy classes.

These pharmacists have specialized knowledge about pharmaceuticals and their use in treating cancer and its comorbidities, and they work collaboratively with the health care team to optimize outcomes.

With orphan drugs under the microscope, it's important to review the special circumstances and challenges of this group.

A rule from CMS requires, in part, that Medicare Advantage organizations and Medicare Part D plan sponsors have the ability to obtain data.

Many factors come into play when establishing a distribution model, and the 3 P's-Pharmacy, Payer, and Product-are all key stakeholders and part of the story.

A new study finds that RSV infections in elderly patients can lead to respiratory failure, prolonged hospitalizations, and morbidity rates similar to those caused by seasonal influenza.